Results 41 to 50 of about 4,521 (193)

Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE [PDF]

, 2023
BACKGROUND: Filgotinib 200 mg (FIL200) is an approved treatment for adults with moderately to severely active ulcerative colitis (UC). AIM: To report integrated safety data from the phase 2b/3 SELECTION study (NCT02914522) and its ongoing long-term ...
Danese, Silvio, de Haas, Angela, Faes, Margaux, Hsieh, Jeremy, Loftus, Edward V, Maaser, Christian, Moerch, Ulrik, Oortwijn, Alessandra, Rogler, Gerhard, Rudolph, Christine, Schreiber, Stefan, Van Hoek, Paul, Vermeire, Séverine, Watanabe, Mamoru, Zhou, Yan   +14 more
core   +1 more source

From Pharmaceutical to Biophysical Therapies: New Horizons in Inflammatory Bowel Disease Management

JCC Plus, Volume 1, Issue 2, March 2026.
Important limitations exist in the current pharmacological landscape of Inflammatory Bowel Disease (IBD), such as variable response rates and treatment‐limiting adverse effects. In this review, we perform a critical assessment of the current literature on novel multimodal biophysical approaches showing alternative mechanisms of action to, and potential
Benedetta Ricchi, Alejandra A. Carriles, Samuel Elias Pineda Chavez, Stefanos Bonovas, Arianna Dal Buono, Cristina Bezzio, Alessandro Armuzzi, Stefania Vetrano   +7 more
wiley   +1 more source

Impact of filgotinib on pain control in the phase 3 FINCH studies [PDF]

Objective This post hoc analysis of the FINCH 1–3 (NCT02889796, NCT02873936 and NCT02886728) studies assessed specific effects of filgotinib on pain control and their relationship with other aspects of efficacy in patients with rheumatoid arthritis (RA).
Alten, Rieke, de Vries, Dick, Fautrel, Bruno, Hasegawa, Ken, Kavanaugh, Arthur, Nash, Peter, Pongratz, Georg, Pope, Janet, Rao, Shangbang, Stiers, Pieter-Jan, Taylor, Peter C, Watson, Chris, Westhovens, Rene   +12 more
core   +2 more sources

Efficacy of Filgotinib for Treating Chronic Antibiotic‐Dependent Pouchitis: A Pilot Study

JCC Plus, Volume 1, Issue 2, March 2026.
Chronic pouchitis after restorative proctocolectomy for ulcerative colitis is often difficult to treat. This study evaluated the efficacy of filgotinib for patients with chronic pouchitis. Some patients with chronic pouchitis may be controlled with filgotinib.
Motoi Uchino, Yuki Horio, Ryuichi Kuwahara, Kurando Kusunoki, Kentaro Nagano, Kazunori Nomura, Yusuke Tomoo, Kozo Kataoka, Kei Kimura, Jihyung Song, Ayako Imada, Kazuma Ito, Yuko Fukumoto, Mizuki Koba, Masataka Ikeda, Hiroki Ikeuchi   +15 more
wiley   +1 more source

JAK Inhibitors for Crohn's Disease: A Systematic Review and Dose–Response Network Meta‐Analysis of Efficacy and Safety

JGH Open, Volume 10, Issue 3, March 2026.
ABSTRACT Crohn's disease has limited effective treatments, and direct comparative data for Janus kinase (JAK) inhibitors are scarce. We conducted a dose‐dependent network meta‐analysis of randomized controlled trials in adults, searching PubMed, Cochrane Library, Scopus, and Web of Science through February 17, 2025. A Bayesian dose–response model (Emax)
Fares A. Qtaishat, Ahmad AlKayyat, Jehad A. Yasin, Mohammad‐Amer A.Tamimi, Jana Tarawneh, Layan AlDaher, Sarah Abdallah, Mohammad Moayad Ahmad Alghaniem, Abdallah Abunamoos, Adham Musa, Yousef A. Ateiwi, Yousef Taha, Tarek A. Tamimi   +12 more
wiley   +1 more source

Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post hoc Analysis of the Phase 2b/3 SELECTION Study [PDF]

BACKGROUND AND AIMS: SELECTION is the first study to assess the impact of concomitant thiopurine and other immunomodulator [IM] use on the efficacy and safety of a Janus kinase inhibitor, filgotinib, in patients with ulcerative colitis.
Danese, Silvio, Faes, Margaux, Fujitani, Yasushi, Hibi, Toshifumi, Lindsay, James O, Oortwijn, Alessandra, Peyrin-Biroulet, Laurent, Rogler, Gerhard, Watanabe, Kenji   +8 more
core   +1 more source

Filgotinib for treating moderate to severe rheumatoid arthritis [PDF]

Prescriber, 2021
Filgotinib (Jyseleca) is a new oral janus kinase (JAK) inhibitor that has recently been approved by NICE for moderate or severe rheumatoid arthritis after failure of other disease‐modifying antirheumatic drugs (DMARDs). This article discusses its efficacy, side‐effects and place in therapy.
openaire   +1 more source

Reshaping study design for faster extrapolation‐based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN–NASPGHAN position paper

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 3, Page 867-894, March 2026.
Abstract Children with inflammatory bowel diseases (IBD) have limited access to the available advanced therapies, given the lengthy gap between adult and pediatric approval. We aimed to review key hurdles for pediatric trials and recommend practical solutions.
Dan Turner, Amit Assa, Mikkel Malham, Shira Yuval Bar‐Asher, Carla Rayan, Jeffrey S. Hyams, Holm H. Uhlig, Brad Pasternak, David C. Wilson, Hilary K. Michel, Lissy de Ridder, Eric Zuckerman, Marina Aloi, Peter Szitanyi, Marla C. Dubinsky, Anne M. Griffiths, Roberto Saldana, Javier Martín‐de‐Carpi, Eytan Wine, Richard K. Russell, Jeremy Adler, Joseph Picoraro   +21 more
wiley   +1 more source

Kinetics of intestinal ultrasound and shear-wave elastography to assess early response in ulcerative colitis patients treated with filgotinib. [PDF]

J Crohns Colitis
Background and Aims A reduction of bowel wall thickness (BWT) on intestinal ultrasound (IUS) predicts endoscopic response in ulcerative colitis (UC). Advanced techniques such as shear-wave elastography (SWE) might enhance response assessment. We aimed to
Pruijt MJ, Teichert C, De Voogd FA, Janssen RJ, Löwenberg M, Goetgebuer RL, D'Haens GR, Gecse KB.   +7 more
europepmc   +2 more sources

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis

Rheumatology and Therapy, 2023
This post hoc analysis of the phase 3 rheumatoid arthritis (RA) filgotinib clinical trial program assessed the effect of filgotinib on body mass index (BMI) in patients with RA and the impact of BMI on the efficacy and safety of filgotinib.FINCH 1-3 were randomized, double-blind, active- or placebo-controlled phase 3 trials of filgotinib 100 and 200 mg
Alejandro Balsa, Siegfried Wassenberg, Yoshiya Tanaka, Anne Tournadre, Hans-Dieter Orzechowski, Vijay Rajendran, Udo Lendl, Pieter-Jan Stiers, Chris Watson, Roberto Caporali, James Galloway, Patrick Verschueren   +11 more
openaire   +6 more sources